Synchrogenix Information Strategies, Inc. acquired by Certara

Our client’s need

Synchrogenix Information Strategies, Inc. and its subsidiaries is a specialty contract research organization providing strategic regulatory writing and related services to pharmaceutical, biotechnology, and medical device companies worldwide. They offer pre-clinical, clinical, CMC, and drug safety writing and submission services. Through its wholly-owned subsidiaries, SynchroWest, Inc.; Synchrogenix Europe Limited; and Synchrogenix Philippines Inc., Synchrogenix provides continuous, global support for its customers.

Our client needed an advisor to guide them through the selling process offering knowledge and experience through the lifecycle of the sale.  They desired a team with experience specific to their industry to help them obtain the best outcome for their company.

Baker Tilly Capital solution

Baker Tilly Capital worked as a close advisor to Synchrogenix during the sale of their business.  Members of our experienced mergers and acquisitions team provided valuable analysis and reporting as it pertained to the value of the business and throughout the transaction. 

Results achieved

Synchrogenix was able to successfully sell their business to Certara, a leading technology-enabled drug development and drug safety consultancy. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. 

For more information on this deal, or to learn how Baker Tilly Capital specialists can help, contact our team.

Baker Tilly Capital, LLC disclosure >
Baker Tilly Capital, LLC privacy policy >